A Decade of Discovery: How China’s Early-Stage Innovations Are Changing the Game in Global Drug Development

A recent study published in Nature Reviews Drug Discovery highlights a profound transformation underway in China’s pharmaceutical sector. Once known for its focus on generic drugs, the country has emerged over the past decade as a rising force in global drug innovation. Driven by regulatory reform, expanded investment channels, and cross-border partnerships, China is now reshaping global dynamics in biopharmaceutical research and commercialization. The implications extend well beyond national borders, offering broader insights into the evolution of innovation ecosystems and the changing geography of pharmaceutical leadership.

From Generics to Global Innovation: A Regulatory-Driven Shift

China’s transformation began in 2015 with a series of sweeping policy changes aimed at streamlining its drug approval process. The Opinions on the Reform of Review and Approval Process for Drugs and Medical Devices targeted long-standing inefficiencies by reducing application backlogs and introducing more predictable review timelines. By 2020, further reforms—including priority review, conditional approval, and breakthrough therapy designations—aligned China’s regulatory environment more closely with global standards.

These changes significantly shortened development cycles and encouraged local startups to enter the market. For multinational firms, the country also became a viable hub for clinical trials and co-development efforts.

This shift marked a departure from China’s historic role as a manufacturer of generic medicines. For decades, the sector focused on scaling production of off-patent drugs, offering little incentive for original R&D. The mid-2010s reforms initiated a pivot from volume to value—laying the groundwork for a domestic industry capable of competing on the strength of innovation rather than replication.

Catalyzing Innovation Through Reform: Lessons from China

China’s reform-first strategy reduced barriers to entry for smaller biotech companies by cutting approval wait times and eliminating redundant processes. Paired with clearer regulatory expectations and mutual recognition of ethics reviews, this created a more attractive environment for early-stage development.

Crucially, the regulatory overhaul was accompanied by broader institutional support. Financial reforms—such as the 18A listing rule in Hong Kong and the STAR Market in Shanghai—enabled pre-revenue biotech firms to access public capital. Investments in clinical trial infrastructure and intellectual property frameworks added further stability to the innovation ecosystem.

As Chinese-developed drugs began receiving approval from international agencies like the U.S. FDA and European EMA, confidence in the country’s capabilities grew. This validation encouraged foreign licensing agreements and cross-border collaborations, offering a model for other emerging markets seeking to foster innovation under structured, state-guided systems.

Record Growth in Innovative Drug Approvals

In 2024, China approved 93 innovative drugs, the highest number in a decade. Of these, 42% were developed domestically, highlighting the country’s growing internal R&D strength. Globally, the country accounted for 39% of first-in-market drug approvals, surpassing Europe and Japan and trailing only the United States.

This rapid acceleration reflects a broader shift in the global regulatory landscape. As China increasingly becomes a launch market for new therapies, regulators worldwide may deepen engagement with the National Medical Products Administration (NMPA). Greater coordination in areas like data-sharing, trial recognition, and review frameworks could follow, particularly in fast-moving fields such as oncology, rare disease, and infectious disease.

For global pharmaceutical companies, this shift introduces new competition. With domestic firms gaining approval both at home and abroad, traditional innovation centers may need to adjust development timelines and trial strategies to maintain their competitive edge.

A Burgeoning Pipeline—and a Long Road Ahead

Between 2015 and 2024, over 4,300 drug candidates developed by Chinese companies entered first-in-human clinical trials. The pipeline is dominated by cell therapies (28%), small molecules (19%), and monoclonal antibodies (9%). However, 89% of these programs remain in Phase I or II, highlighting limited late-stage maturity.

The volume of early-stage R&D reflects expanding discovery capacity, but the slower transition to commercialization suggests lingering challenges. Factors such as complex trial design, limited late-phase infrastructure, and evolving regulatory expectations may be contributing to this stage imbalance.

Therapeutic areas such as autoimmune diseases, neurological conditions, and rare disorders remain underrepresented relative to domestic and global health needs. In parallel, emerging modalities like RNA-based therapeutics, bispecific antibodies, and targeted protein degraders remain in early development, but may see increased activity as clinical capabilities advance.

Capital Inflows—and the Inevitable Cooling

China’s biopharma sector attracted over ¥418 billion (~US$60 billion) in primary market funding over the past decade, peaking in 2021. Major reforms, such as Hong Kong’s 18A listing rule and the STAR Market launch, opened the door for pre-revenue innovators to access public capital. But post-2021, investment began to wane due to regulatory tightening, macro-economic shifts, and investor caution.

This investment boom was a natural reaction to early-stage policy tailwinds and market optimism. However, with oversaturation, inflated valuations, and low return on R&D investments, the correction was perhaps inevitable. During the peak years, many companies pursued similar therapeutic targets—particularly in oncology—leading to highly competitive pipelines with limited differentiation. As a result, some assets struggled to progress through late-stage trials or to secure market access, causing investor sentiment to cool. The sharp drop in valuations also reflects a broader reassessment of risk, where financial backers are prioritizing quality of science and clinical strategy over sheer pipeline volume.

In the near term, we’re likely to see fewer but more disciplined deals, especially in high-potential and underdeveloped segments such as antibody–drug conjugates (ADCs), nucleic acid therapies, and radiopharmaceuticals. These areas not only align with global R&D trends but also present clearer market entry opportunities due to their targeted mechanisms, ability to address unmet clinical needs, and potential for faster regulatory pathways if early clinical data is strong. Venture capital is expected to shift from broad, high-volume funding toward programs with distinctive platforms, well-defined translational potential, and commercialization strategies that meet both domestic and international market requirements. This focus on differentiated science will likely encourage companies to invest in novel therapeutic classes, improved manufacturing technologies, and precision medicine approaches, all of which are gaining traction with regulators and payers alike.

Global Ambitions Take Shape Through Licensing

Since 2019, Chinese-origin drugs have begun to secure overseas approvals. By 2024, 18 drugs developed in China received foreign regulatory clearance, including entries into the U.S., EU, and emerging markets. Oncology dominates this export landscape, with over 60% of approvals tied to PD-1 inhibitors, cell therapies, and small-molecule cancer drugs.

But most significantly, Chinese firms are embracing out-licensing as a globalization strategy.

2024 snapshot:

• 94 out-licensing deals completed
• US$51.9 billion in potential deal value
• 64% of deals involved preclinical-stage assets
• U.S. companies accounted for 47% of all licensing partners

What this means is that, rather than go it alone, Chinese companies are strategically partnering with global firms to leverage foreign regulatory expertise and commercialization channels. This reflects a mature understanding of the complexities of scaling globally—and a practical response to capital constraints and competitive pressures at home.

Challenges on the Horizon

Despite a decade of momentum, China’s pharmaceutical evolution still faces structural hurdles:

• Lack of truly original innovation: Many drugs are variations or fast followers.
• Overcrowded pipelines: Too many companies chase similar targets.
• Market constraints: Despite approval, many drugs struggle to reach hospitals or generate sustainable revenue due to reimbursement policies and price cuts.

Strategic response:

The 2024 “Full-Chain Support Plan for Innovative Drugs” aims to address these gaps. It focuses on:

• Encouraging first-in-class innovation
• Supporting IPOs and M&As
• Optimizing regulatory coordination
• Improving market adoption and reimbursement pathways

Looking Ahead: A Global Stake in China’s Innovation Future

China’s rise in biopharma signals more than domestic advancement—it reflects a broader decentralization of innovation. While the United States remains a dominant force, China’s growing influence is reshaping expectations around talent mobility, capital allocation, IP strategy, and regulatory engagement.

For multinational pharma companies, this means:

• Watching China not just as a market, but as a source of innovation
• Competing for partnerships or pipeline access to emerging Chinese biotech
• Preparing for a multipolar innovation economy, where first-in-class breakthroughs may come from a broader set of geographies

For policymakers, the message is clear: fostering innovation requires long-term regulatory foresight, financial incentives, and global integration—lessons that transcend national borders.

China’s pharmaceutical ascent is not just reshaping its domestic market—it’s rewriting the rules of global biopharma. As regulatory reforms mature, capital flows stabilize, and innovation pipelines deepen, the global industry will need to adapt to a more interconnected, competitive, and diversified future. The next decade won’t be about where a drug is made—but where innovation is sparked, scaled, and shared.

Author

Bernice Lottering